Showing 4701-4710 of 5646 results for "".
- Santen and Aerie Conclude Exclusive License Agreement for Rhopressa and Rocklatan in Japan and Several Other Asian Countrieshttps://modernod.com/news/santen-and-aerie-conclude-exclusive-license-agreement-for-rhopressa-and-rocklatan-in-japan-and-several-other-asian-countries/2478469/Santen Pharmaceutical and Aerie Pharmaceuticals announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa and Rocklatan in Japan, along with rights for several other Asian countries. Rhopressa (netarsudil ophthalmic solution) 0
- iVeena Announces Positive Topline Results of IVMED-80 Eye Drops for Keratoconushttps://modernod.com/news/iveena-announces-positive-topline-results-of-ivmed-80-eye-drops-for-keratoconus/2478466/iVeena has announced topline results of its recently completed phase 1/2a clinical trial, “A Randomized, Double-Masked, Trial of IVMED-80 Eyedrops for Treatment of Keratoconus.” The study objective was to determine whether a 6- or 16-week course of twice-daily IVMED-80 eyedrops (vs. placebo) coul
- AstraZeneca’s COVID-19 Vaccine Produces Robust Immune Response in Elderlyhttps://modernod.com/news/astrazenecas-covid-19-vaccine-produces-robust-immune-response-in-elderly/2478462/AstraZeneca disclosed that its experimental COVID-19 vaccine AZD1222 triggered a robust immune response in elderly and older adults, similar to that previously seen in healthy study volunteers aged between 18 and 55. Adverse events associated with the vaccine, which is being co-developed with the
- AstraZeneca, J&J Say Their COVID-19 Vaccine Trials Back on Track in UShttps://modernod.com/news/astrazeneca-jj-say-their-covid-19-vaccine-trials-back-on-track-in-us/2478455/AstraZeneca announced Friday that it has been cleared to restart its phase 3 COVID-19 vaccine trial in the US. The company, which is co-developing AZD1222 with the University of Oxford, had paused global testing of the vaccine candidate early last month after a UK participant fell ill with what i
- Visus Therapeutics Expands Clinical Advisory Board With Appointment of Renowned Ophthalmologistshttps://modernod.com/news/visus-therapeutics-expands-clinical-advisory-board-with-appointment-of-renowned-ophthalmologists/2478453/Visus Therapeutics announced the appointments of prominent ophthalmologists Marguerite McDonald, MD, Neda Shamie, MD, William Trattler, MD, and Lawrence Woodard, MD, to its clinical advisory board. Drs. McDonald, Shamie, Trattler and Woodard will lend their decades of experience in clinical pract
- Moderna Hits 30,000 Enrollment Target in Phase 3 Coronavirus Vaccine Trialhttps://modernod.com/news/moderna-hits-30000-enrollment-target-in-phase-3-coronavirus-vaccine-trial/2478450/Moderna announced that it has completed enrollment of 30,000 participants in the phase 3 COVE study of its investigational coronavirus vaccine mRNA-1273. More than 25,650 participants have so far received their second dose, and Moderna said it will decide whether to seek emergency-use autho
- Rayner Launches Raytrace Premium IOL Calculator Update to Include Posterior Corneal Astigmatismhttps://modernod.com/news/rayner-launches-raytrace-premium-iol-calculator-update-to-include-posterior-corneal-astigmatism/2478444/Rayner announced the launch of their updated web-based premium IOL calculator, Raytrace. Developed in line with surgeon feedback, the new Raytrace version 3.5 includes the following improvements: Inclusion of Posterior Corneal Astigmatism (PCA) for more accurate toric IOL calculation
- Nevakar Enters into Licensing Agreement in China for NVK-002 for the Treatment of Myopia in Childrenhttps://modernod.com/news/nevakar-enters-into-licensing-agreement-in-china-for-nvk-002-for-the-treatment-of-myopia-in-children/2478434/Nevakar and Hong Kong-based Zhaoke Ophthalmology Pharmaceutical (ZKO) announced have entered into an exclusive licensing agreement for the development and commercialization of Nevakar’s NVK-002 in Greater China, Hong Kong SAR, Macau SAR and Taiwan, South Korea and the Southeast Asian territories.
- Katena Products Acquires Micro-Select Instrumentshttps://modernod.com/news/katena-products-acquires-micro-select-instruments/2478435/Katena Products announced the purchase of Micro-Select Instruments, a maker of ophthalmic instruments including forceps, needle holders, and speculums. Terms of the deal were not disclosed. “The acquisition of Micro-Select is an important addition to Katena’s growing instrument manu
- Allergan Announces Updates to Eye Care Optometric Professional Relations Teamhttps://modernod.com/news/allergan-announces-updates-to-eye-care-optometric-professional-relations-team/2478432/Allergan Eye Care announced the retirement of Dave Gibson, Associate VP of Consumer Eye Care and Customer Development, after 20 years of service. Since 2009, Mr. Gibson has led Allergan’s Optometric Professional Relations team and helped launch a variety of programs to support the optometry com